| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
14,177 |
12,790 |
$2.78M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
20,474 |
18,347 |
$2.18M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
3,811 |
3,309 |
$908K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
11,524 |
9,954 |
$391K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
25,297 |
10,867 |
$311K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
2,535 |
2,257 |
$220K |
| 71045 |
Radiologic examination, chest; single view |
4,892 |
4,193 |
$215K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
6,225 |
4,954 |
$183K |
| 70450 |
Computed tomography, head or brain; without contrast material |
803 |
694 |
$176K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
942 |
454 |
$118K |
| 80053 |
Comprehensive metabolic panel |
17,692 |
14,417 |
$105K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
112 |
94 |
$104K |
| 80050 |
General health panel |
2,515 |
2,254 |
$102K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,477 |
2,154 |
$89K |
| 86403 |
|
8,039 |
7,020 |
$73K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
698 |
388 |
$73K |
| G0378 |
Hospital observation service, per hour |
728 |
534 |
$71K |
| 36415 |
Collection of venous blood by venipuncture |
36,743 |
29,094 |
$69K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
2,189 |
1,923 |
$67K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
2,204 |
1,924 |
$67K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
14,570 |
12,098 |
$67K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
2,644 |
2,273 |
$56K |
| 71046 |
Radiologic examination, chest; 2 views |
886 |
813 |
$54K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,112 |
978 |
$52K |
| 80061 |
Lipid panel |
4,820 |
4,299 |
$47K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
86 |
77 |
$44K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
411 |
362 |
$43K |
| 83735 |
|
9,708 |
7,718 |
$37K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
78 |
70 |
$34K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,437 |
2,094 |
$33K |
| 84484 |
|
5,321 |
3,886 |
$32K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
188 |
165 |
$32K |
| 83880 |
|
1,815 |
1,560 |
$31K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
19,395 |
15,603 |
$30K |
| 82607 |
|
2,189 |
1,922 |
$23K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
3,266 |
2,855 |
$22K |
| 76830 |
Ultrasound, transvaginal |
113 |
102 |
$21K |
| 81001 |
|
8,867 |
7,650 |
$18K |
| 84466 |
|
1,872 |
1,622 |
$17K |
| 94664 |
|
945 |
401 |
$15K |
| 84703 |
|
2,319 |
2,016 |
$15K |
| 82553 |
|
2,870 |
2,135 |
$14K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
161 |
120 |
$14K |
| 82550 |
|
4,304 |
3,127 |
$13K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
547 |
459 |
$13K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
676 |
585 |
$13K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
188 |
146 |
$12K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
2,239 |
1,937 |
$12K |
| 84439 |
|
1,738 |
1,491 |
$12K |
| 87186 |
|
1,429 |
1,081 |
$11K |
| 87070 |
|
1,455 |
1,265 |
$11K |
| 87077 |
|
1,130 |
882 |
$9K |
| 83540 |
|
1,906 |
1,656 |
$8K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,074 |
944 |
$8K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
17 |
14 |
$8K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,236 |
641 |
$8K |
| J2785 |
Injection, regadenoson, 0.1 mg |
42 |
41 |
$8K |
| 85379 |
|
1,140 |
1,020 |
$7K |
| 87210 |
|
1,425 |
1,213 |
$6K |
| 93017 |
|
104 |
94 |
$6K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
874 |
748 |
$6K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
268 |
248 |
$6K |
| 82728 |
|
755 |
636 |
$6K |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
95 |
85 |
$5K |
| 87420 |
|
473 |
405 |
$5K |
| 84145 |
|
372 |
314 |
$5K |
| 83690 |
|
1,192 |
1,022 |
$5K |
| 85730 |
|
1,688 |
1,509 |
$5K |
| 87807 |
|
382 |
323 |
$4K |
| 85610 |
|
2,030 |
1,783 |
$4K |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
76 |
70 |
$4K |
| 82746 |
|
408 |
347 |
$3K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
15 |
12 |
$3K |
| 82043 |
|
630 |
569 |
$3K |
| 83525 |
|
313 |
273 |
$3K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
134 |
36 |
$3K |
| 81003 |
|
1,739 |
1,523 |
$3K |
| 83704 |
|
208 |
168 |
$3K |
| 80074 |
|
56 |
53 |
$2K |
| 84144 |
|
108 |
100 |
$2K |
| 84480 |
|
294 |
267 |
$2K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
624 |
389 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
190 |
164 |
$1K |
| 87040 |
|
280 |
139 |
$1K |
| 83605 |
|
245 |
192 |
$1K |
| 73130 |
|
14 |
13 |
$1K |
| 90686 |
|
122 |
108 |
$1K |
| 73630 |
|
17 |
14 |
$1K |
| 93925 |
|
49 |
14 |
$1K |
| 84443 |
Thyroid stimulating hormone (TSH) |
216 |
192 |
$959.79 |
| 86592 |
|
231 |
224 |
$899.25 |
| 82948 |
|
366 |
93 |
$827.52 |
| 84403 |
|
32 |
30 |
$722.68 |
| 84402 |
|
32 |
30 |
$713.16 |
| 93922 |
|
94 |
38 |
$643.82 |
| 86480 |
|
13 |
12 |
$619.80 |
| 0003A |
|
13 |
13 |
$612.04 |
| 84481 |
|
40 |
39 |
$537.20 |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
12 |
12 |
$473.70 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
33 |
29 |
$416.13 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
43 |
37 |
$368.16 |
| 82670 |
|
17 |
15 |
$363.22 |
| 86140 |
|
100 |
86 |
$331.53 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
13 |
13 |
$308.52 |
| 82626 |
|
12 |
12 |
$303.24 |
| 82627 |
|
13 |
13 |
$288.99 |
| Q3014 |
Telehealth originating site facility fee |
184 |
155 |
$269.93 |
| 84270 |
|
12 |
12 |
$260.76 |
| Q0177 |
Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
87 |
61 |
$234.60 |
| 83002 |
|
12 |
12 |
$222.24 |
| 82533 |
|
13 |
13 |
$211.90 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
12 |
12 |
$201.46 |
| 82150 |
|
44 |
39 |
$188.98 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
65 |
38 |
$173.17 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
37 |
26 |
$165.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
647 |
483 |
$158.94 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
30 |
25 |
$152.00 |
| 86803 |
|
13 |
12 |
$142.70 |
| 82397 |
|
14 |
14 |
$88.34 |
| 83615 |
|
30 |
26 |
$84.56 |
| 99406 |
|
113 |
103 |
$83.86 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
13 |
13 |
$78.95 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
14 |
12 |
$76.16 |
| 96376 |
|
108 |
31 |
$64.30 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
13 |
13 |
$60.75 |
| 85651 |
|
16 |
13 |
$42.70 |
| 86141 |
|
13 |
13 |
$38.85 |
| 85027 |
|
14 |
13 |
$38.82 |
| 85007 |
|
36 |
28 |
$37.51 |
| 1159F |
|
606 |
494 |
$0.44 |
| 1126F |
|
390 |
325 |
$0.21 |
| 3078F |
|
86 |
76 |
$0.06 |
| 96160 |
|
20 |
17 |
$0.05 |
| 1125F |
|
65 |
54 |
$0.04 |
| 1160F |
|
38 |
38 |
$0.04 |
| 3074F |
|
33 |
29 |
$0.02 |
| 1220F |
|
460 |
366 |
$0.02 |
| 3077F |
|
16 |
13 |
$0.02 |
| J2704 |
Injection, propofol, 10 mg |
69 |
51 |
$0.00 |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
40 |
36 |
$0.00 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
12 |
12 |
$0.00 |
| 00000 |
|
371 |
357 |
$0.00 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
41 |
26 |
$0.00 |
| 91300 |
|
28 |
27 |
$0.00 |
| G0179 |
Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care |
39 |
39 |
$0.00 |
| T1015 |
Clinic visit/encounter, all-inclusive |
19 |
15 |
$0.00 |